UNSPSC 51182406: Alendronic acid or alendronate sodium

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C4H13NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1J18R4W8P, chemically known as 4-amino-1-hydroxybutylidene-1,1-bis(phosphonic acid) but generally known as alendronate, which bears US NIH Compound Identifier 2088. Alendronate comes in forms hydrate, sodium, and trihydrate. European Medicines Agency schedules Alendronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05307MIG.

UNSPSC 51182406 Alendronic acid or alendronate sodium is a Commodity code representing pharmaceutical products used to treat osteoporosis and related bone conditions. State and local procurement activity under this code shows little relevance to its nominal scope; recent opportunities tagged with this code do not include alendronate sodium or related osteoporosis medications. The most recent state and local contract opportunities posted under this code are a District Attorney's Office Dog solicitation from Washington County, Oregon (RFP, due August 14, 2026), athletic training services for fire and police departments from the City of Tucson (RFP, due June 9, 2026), and medical aid supplies from the City of Tampa Fire Rescue Department (ITB, due April 9, 2025). None of these solicitations involve alendronate sodium or pharmaceutical procurement in the osteoporosis therapeutic category. The tagging mismatch suggests either classification error in the issuing bodies' systems or that this code sees minimal actual procurement activity aligned with its stated product scope.

The geographic distribution reflected in recent opportunities spans Oregon, Arizona, and Florida, though the sample is too small to characterize broader market concentration. Given the absence of alendronate sodium or related bone-health pharmaceutical solicitations in the recent opportunities block, this code does not present a clear procurement pathway for vendors supplying osteoporosis medications to state and local governments at this time.